Genomtec S.A. (WSE: GMT)
Health Care · Biotechnology · PL
zł3.73
-2.86% today · -38.9% 1Y
Genomtec S.A. (WSE: GMT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.56M and employs 32 people.
Over the last twelve months the share price has lost 38.9%, trading between 3.25 and 7.33.
Tweenvest scores Genomtec S.A. across four factors: quality 26/100, value 32/100, growth 50/100. Its strongest factor is growth.
GMT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.56M
- Revenue (TTM)
- $8.05K
- P/E
- —
- EPS
- -0.61
- Dividend yield
- —
- Beta (5Y)
- 0.31
- 52-week high
- zł7.33
- 52-week low
- zł3.25
- Avg volume (3M)
- —
- Shares outstanding
- 15.06M
- Employees
- 32
- Next earnings
- —
About Genomtec S.A.
Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated to the research, development, manufacturing, and global commercialization of advanced molecular diagnostic products. The company's expertise lies in optical systems and isothermal nucleic acid amplification methodologies. A core offering is Genomtec ID, a portable technological device designed for on-the-go genetic diagnostics. This system employs streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, fungi, and genetic mutations through the analysis of patient biological materials like swabs, urine, saliva, blood, and other bodily fluids. Furthermore, Genomtec has developed Genomtec Tumor, a SNAAT-based solution for identifying neoplastic mutations and those with prognostic value in cancer diagnoses. The company also offers diagnostic kits for COVID-19, including the Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit, which detects SARS-CoV-2 RNA in samples from individuals suspected of infection, and the Genomtec RT-LAMP CE-IVD Duo-Kit, capable of identifying all variants of the SARS-CoV-2 virus.
- ISIN
- PLGNMTC00017
- Founded
- 2016
- Listed since
- Mar 17, 2021
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.